PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629221
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629221
Iliac Stent Market size was valued at US$ 1,123.45 Million in 2024, expanding at a CAGR of 5.9% from 2025 to 2032.
The Iliac Stent Market focuses on medical devices to treat iliac artery stenosis, ensuring adequate blood flow to the lower limbs. The increasing prevalence of peripheral artery disease (PAD), affecting over 200 million people globally according to WHO, is a major factor fueling market demand. The growing geriatric population, advancements in stent technology, and rising adoption of minimally invasive procedures also contribute to the market's expansion. However, high costs associated with stent placement and risks of complications like restenosis pose significant challenges. Opportunities lie in developing bioresorbable stents and expanding healthcare access in emerging economies. For example, healthcare reforms in countries like India and Brazil drive investments in advanced cardiovascular devices, presenting growth potential for the iliac stent market. Enhanced patient outcomes and reduced recovery times with modern stents further encourage adoption across developed and developing regions alike.
Iliac Stent Market- Market Dynamics
Rising Prevalence of Peripheral Artery Disease Boosts Demand for Iliac Stents
The rising prevalence of peripheral artery disease (PAD) is significantly driving the demand for iliac stents, as these devices are critical for restoring blood flow in blocked iliac arteries. According to the World Health Organization (WHO), PAD affects over 200 million people globally, particularly impacting older adults and individuals with diabetes or smoking habits. The American Heart Association highlights that untreated PAD can lead to serious complications, including critical limb ischemia. To address this growing burden, healthcare providers are increasingly adopting advanced stent technologies that offer better durability, flexibility, and patient outcomes. For instance, modern self-expanding and drug-eluting stents are helping reduce restenosis rates and improving long-term efficacy, making them essential tools in minimally invasive vascular procedures. Furthermore, government initiatives aimed at improving access to advanced cardiovascular care in emerging economies are expanding opportunities for iliac stent adoption, ensuring improved quality of life for patients with PAD.
Iliac Stent Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.9% over the forecast period (2025-2032)
Based on Type segmentation, Balloon-Expandable Stents were predicted to show maximum market share in the year 2024
Based on Material segmentation, Metallic Stents was the leading Material in 2024
Based on region, North America was the leading revenue generator in 2024
The Global Iliac Stent Market is segmented based on Type, Material, Application, End-User, and Region.
The market is divided into two categories based on Type: Balloon-Expandable Stents and Self-Expanding Stents. Balloon-expandable stents are prioritized for their precise placement and effective use in complex iliac artery lesions, making them ideal for critical cases. Self-expanding stents follow, valued for their flexibility and adaptability in challenging or tortuous vascular anatomies.
The market is divided into two categories based on Material: Metallic Stents and Polymeric Stents. Metallic stents hold higher priority due to their durability, proven performance, and widespread use in iliac artery procedures. Polymeric stents follow, gaining attention for their potential in bioresorbable applications but are currently limited by lower availability and long-term data.
Iliac Stent Market- Geographical Insights
The Iliac Stent Market demonstrates varied growth dynamics across regions, influenced by healthcare infrastructure, disease prevalence, and technological advancements. North America leads the market, driven by a high prevalence of peripheral artery disease (PAD), advanced healthcare systems, and substantial investments in minimally invasive procedures. The U.S. plays a key role in a growing aging population and increasing awareness of vascular health. Europe follows closely, with countries like Germany, France, and the UK focusing on advanced vascular treatments supported by favorable reimbursement policies. Asia-Pacific is emerging as a lucrative market due to a rising geriatric population, increasing incidence of PAD, and expanding healthcare access in countries like China, India, and Japan. Government initiatives to improve cardiovascular care further bolster the market. Latin America and the Middle East & Africa exhibit slower growth, primarily due to limited healthcare resources, but improving healthcare infrastructure and rising awareness present significant future opportunities. These regions are expected to gradually adopt advanced iliac stent technologies to address unmet medical needs.
The Iliac Stent Market is highly competitive, with key players focusing on innovation, product development, and strategic collaborations to strengthen their market presence. Major companies such as Boston Scientific, Medtronic, Abbott Laboratories, and Terumo Corporation dominate the market. These firms invest heavily in research and development to create advanced stent technologies, such as drug-eluting and bioresorbable stents, aimed at improving patient outcomes and reducing complications like restenosis. Boston Scientific and Medtronic are leading the way with their balloon-expandable and self-expanding stents, which have become the preferred choice for treating iliac artery diseases. Regional players like Cook Medical and Cordis are also strengthening their positions, focusing on offering cost-effective solutions in emerging markets. Additionally, companies are forming strategic alliances with healthcare providers to expand their market reach and gain a competitive edge. As the demand for minimally invasive procedures increases, firms are adopting cutting-edge technologies like bioresorbable materials and advancing manufacturing capabilities to cater to a diverse patient base across various regions.
In July 2019, Terumo Corporation launched the MISAGO(TM) RX Self-expanding Peripheral Stent for iliac arteries in Japan, effective mid-July 2019. This stent enhances treatment options for peripheral artery disease (PAD) and aims for a 25% market share in the local market.
In October 2023, Getinge announced the U.S. commercial availability of the iCast-covered stent system for treating iliac arterial occlusive disease. This follows its premarket approval by the FDA in March 2023, enhancing treatment options for lower extremity peripheral artery disease.